People demand better alternatives

Our Transformation

Delivering a smoke-free future

We're one of the world's leading tobacco companies, and we're committed to finding alternatives to cigarettes as quickly as possible.

5 min to read
Read article
img_pmi_homepage_banner_regulation_block-v3

It's Time

Why can't we talk about our better alternatives?

3 min read
1-thumb-goal-v2

Our Transformation

Our goal and strategies

3 min read
blue-gradient

Discover who we are

Philip Morris International has a diverse workforce of around 77,000 people who hail from every corner of the globe.

3 min read
Our Science
Our Science
Cutting-edge research and technology
problem-with-burning

The problem with burning

3 min read
Read article
L3_thumbnail_RoleOfNicotine
The role of nicotine 3 min read
join-the-conversation
A demand for less harmful alternatives 4 min read
robust-science-and-rigorous-testing

Our findings to date

What are our scientific studies saying about our breakthrough products?

5 min read
Moira op-ed speaking out
Speaking out when it's not safe 4 min read
Common sense approach to public health
A common-sense approach for public health 2 min read
Our initiatives
Our initiatives
Campaigning for a smoke-free future
its-time

It's Time

It's Time to Unsmoke: Why now?

PMI wants to start conversations about smoking alternatives

5 min read
Read article
People talking cartoon thumbnail
It's Time It's Time to talk facts 5 min read
its time start conversation
It's Time Why can't we say more 5 min read
clock time its time thumbnail

It's Time

It's Time: Frequently asked questions

5 min read
17.07.18_PMI_DAY02_02471_F1
It's Time It's time to join the conversation 5 min read
QA-moira
It's Time PMI's Dr. Moira Gilchrist on the 'It's Time' initiative 5 min read

In the spotlight
3:47 to watch
1:18 to watch
1:14 to watch
1:15 to watch
6:28 to watch
1:31 to watch
1:07 to watch
0:50 to watch
0:59 to watch
0:27 to watch
Smoke-Free Life
Smoke-Free Life
Go beyond your past, make a positive change
Astypalea-boat-crop-1

Smoke-Free Life

Welcome to the world's first smoke-free island

The Greek island of Astypalea is moving towards a smoke-free future, and encouraging tourists and locals alike to quit completely or change to smoke-free alternatives on this tiny slice of paradise.

5 min read
Read article
YSL Le Smoking Getty crop

The fashion industry turns its back on smoking

5 min read
Unsmoke Q&A alternative

Busting common myths around smoke-free alternatives

5 min read
pmi-emblem

Why Invest in PMI?

We've built the worlds most succesful cigarette company. Now we're building our future on smoke-free products that are much better choices.

$ 8479

1.37 (1.64%)

Investor Relations

Latest Press Releases

Media Center

  • News 13 Nov, 2019

    Learning, adapting, transforming: New PMI employees on their first 100 days

  • News 12 Nov, 2019

    A model for change: PMI’s Agricultural Labor Practices program

  • News 08 Nov, 2019

    An unsustainable trade: PMI is supporting the MSC initiative to tackle the problem of illicit trade

  • News 08 Nov, 2019

    Taking responsibility: Why companies considered to be part of the problem should be part of the solution

This site is operated for the purpose of providing general information about us. The site is not operated for advertising or marketing purposes. The material on this site should not be regarded as an offer to sell, or a solicitation of an offer to buy, any product of PMI. Such products are sold only in compliance with the laws of the particular jurisdictions in which they are sold. IQOS and other smoke-free products under development by PMI are not currently available in the U.S. . PMI has now been granted authorization to market IQOS 2.4 in the U.S. from the Food and Drug Administration (FDA), which Altria will bring to the U.S. market under the terms of a license from PMI. The FDA has not yet determined whether IQOS 2.4 meets the standard to be marketed in the U.S. as a modified risk tobacco product. PMI’s applications to the FDA seeking authorization to market IQOSin the U.S. as a modified risk product are currently under review.